Literature DB >> 9392430

Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis.

R Garuti1, M A Croce, R Tiozzo, M T Dotti, A Federico, S Bertolini, S Calandra.   

Abstract

We report the characterization of eight mutations of sterol 27-hydroxylase gene (CYP27) in five Italian patients with cerebrotendinous xanthomatosis, who were found to be compound heterozygotes. Four mutations (C --> T at nt 45 of exon 4, G(+1) --> A in intron 6, G(+5) --> T in intron 7, and G(-1) --> A in intron 7) are novel. The C --> T at nt 45 of exon 4 converts the arginine codon into a stop codon thus generating a truncated protein of 198 amino acids. The three splice site mutations reduced the content of CYP27 mRNA in skin fibroblasts to very low or undetectable levels and generated minute amounts of abnormal mRNAs. The G(+1) --> A transition in intron 6 produced three abnormal mRNAs. In the first, the 5' half of exon 6 joins to exon 7, skipping 89 bp of exon 6, and in the second, exon 5 joins directly to exon 7. The predicted translation products of these mRNAs are truncated proteins. In the third abnormal mRNA, exon 5 joins to exon 8 with an in-frame deletion of 246 bp. The G(+5) --> T transversion in intron 7 generates a single abnormal mRNA in which exon 6 joins directly to exon 8, with a frameshift and a premature stop codon. In the G(-1) --> A transition in intron 7, two mRNAs are generated. In the first, the retention of the whole intron 7 causes a frameshift and a premature stop codon; in the second, the joining of exon 7 to exon 8 is associated with an in-frame deletion of the first 6 nucleotides. All these novel mutations are predicted to produce structurally abnormal enzymatic proteins with no measurable biological activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392430

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  [Cerebrotendinous xanthomatosis--a treatable metabolic disorder].

Authors:  J P Sperhake; J Matschke
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

2.  Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.

Authors:  M T Dotti; A Rufa; A Federico
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees.

Authors:  M H Lee; S Hazard; J D Carpten; S Yi; J Cohen; G T Gerhardt; G Salen; S B Patel
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

4.  Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy.

Authors:  Germaine Pierre; Kenneth Setchell; Jacqueline Blyth; Mary Anne Preece; Anupam Chakrapani; Patrick McKiernan
Journal:  J Inherit Metab Dis       Date:  2008-12-27       Impact factor: 4.982

5.  Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports.

Authors:  Maria Donata Di Taranto; Monica Gelzo; Carola Giacobbe; Marco Gentile; Gennaro Marotta; Silvia Savastano; Antonio Dello Russo; Giuliana Fortunato; Gaetano Corso
Journal:  Metab Brain Dis       Date:  2016-05-26       Impact factor: 3.584

6.  Late-Onset Leukodystrophy Mimicking Hereditary Spastic Paraplegia without Diffuse Leukodystrophy on Neuroimaging.

Authors:  Tongxia Zhang; Chuanzhu Yan; Yiming Liu; Lili Cao; Kunqian Ji; Duoling Li; Lingyi Chi; Yuying Zhao
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-12       Impact factor: 2.570

Review 7.  What's in a Gene? The Outstanding Diversity of MAPT.

Authors:  Daniel Ruiz-Gabarre; Almudena Carnero-Espejo; Jesús Ávila; Vega García-Escudero
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.